According to the information updated on the website of the National Medical Products Administration of China (NMPA) on May 30, the marketing approval progress of the Camrelizumab for Injection independently developed by Hengrui Medicine was updated to “Approval completed-to be issued certificate”, which means that the camrelizumab of Hengrui will finally be marketed after 15 months!
